|
84 Companies |
|
139 Products |
|
139 Products |
|
62 Mechanisms of Action |
|
7 Trials |
|
632 News |
|
| «12345678910111213...1314» |
- || ontuxizumab (MORAb-004) / Eisai
Enrollment closed: MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma (clinicaltrials.gov) - Jan 12, 2015
P1, N=65, Active, not recruiting, Sponsor: Morphotek
Recruiting --> Active, not recruiting
- deferasirox tablet for oral suspension / Generic mfg.
Trial completion: Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies (clinicaltrials.gov) - Jan 2, 2015
P=N/A, N=16, Completed, Sponsor: Comprehensive Cancer Center of Wake Forest University
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || ontuxizumab (MORAb-004) / Eisai
Trial initiation date: MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma (clinicaltrials.gov) - Dec 19, 2014
P1, N=65, Recruiting, Sponsor: Morphotek
Active, not recruiting --> Completed Initiation date: Aug 2013 --> Nov 2013
- peripheral blood stem cell transplantation / National Cancer Institute
Trial initiation date, Gene therapy: Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma (clinicaltrials.gov) - Dec 17, 2014
P=N/A, N=13, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Initiation date: Aug 2013 --> Nov 2013 Initiation date: Oct 2014 --> Feb 2015
- alisertib (MLN8237) / Puma, Rituxan (rituximab) / Roche
Trial primary completion date, Combination therapy: Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Dec 12, 2014
P2, N=50, Recruiting, Sponsor: Kristie Blum
Initiation date: Oct 2014 --> Feb 2015 Trial primary completion date: Jun 2014 --> Dec 2015
- Enrollment change, Trial termination, Trial primary completion date: Presence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell Transplant (clinicaltrials.gov) - Dec 10, 2014
P1, N=24, Terminated, Sponsor: Vanderbilt University
Trial primary completion date: Jun 2014 --> Dec 2015 N=50 --> 24 | Recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Dec 2014; PI leaving institution
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma, Rituxan (rituximab) / Roche
Enrollment open, Trial initiation date, Trial primary completion date, Combination therapy: CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Dec 6, 2014
P1, N=14, Recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
N=50 --> 24 | Recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Dec 2014; PI leaving institution Not yet recruiting --> Recruiting | Initiation date: Aug 2014 --> Dec 2014 | Trial primary completion date: Aug 2016 --> Dec 2016
- Enrollment closed, Trial primary completion date, Metastases: AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma (clinicaltrials.gov) - Nov 23, 2014
P1, N=60, Active, not recruiting, Sponsor: Craig Hofmeister
Not yet recruiting --> Recruiting | Initiation date: Aug 2014 --> Dec 2014 | Trial primary completion date: Aug 2016 --> Dec 2016 Recruiting --> Active, not recruiting | Trial primary completion date: May 2013 --> Jun 2015
- Zolinza (vorinostat) / Merck (MSD)
Trial completion, Trial primary completion date: Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies (clinicaltrials.gov) - Nov 13, 2014
P2, N=12, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial primary completion date: May 2013 --> Jun 2015 Active, not recruiting --> Completed | Trial primary completion date: Jun 2014 --> Mar 2014
- RG4733 / Roche
Trial completion, Combination therapy: RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors (clinicaltrials.gov) - Nov 7, 2014
P1, N=30, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial primary completion date: Jun 2014 --> Mar 2014 Active, not recruiting --> Completed
- ||||| Istodax (romidepsin) / Astellas, BMS, Rituxan (rituximab) / Roche
New P1/2 trial: Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Nov 3, 2014
P1/2, N=56, Not yet recruiting, Sponsor: Mayo Clinic
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion: Rituximab Combined With Chemotherapy in Burkitt's Lymphoma (clinicaltrials.gov) - Oct 28, 2014
P2, N=20, Completed, Sponsor: PETHEMA Foundation
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | human allogeneic myeloid progenitor cells (CLT-008) / Cellerant Therap
Trial completion, Post-transplantation: Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy (clinicaltrials.gov) - Oct 27, 2014
P1, N=30, Completed, Sponsor: Cellerant Therapeutics
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Monjuvi (tafasitamab-cxix) / Incyte
Trial primary completion date: Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL) (clinicaltrials.gov) - Oct 22, 2014
P2a, N=30, Recruiting, Sponsor: MorphoSys AG
Active, not recruiting --> Completed Trial primary completion date: Jul 2014 --> Mar 2015
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Roche
Trial completion: Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia (clinicaltrials.gov) - Oct 22, 2014
P2, N=105, Completed, Sponsor: Cancer and Leukemia Group B
Trial primary completion date: Jul 2014 --> Mar 2015 Active, not recruiting --> Completed
- | Epogen (epoetin alfa) / Amgen, Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Phase classification: Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy (clinicaltrials.gov) - Oct 17, 2014
P2, N=320, Completed, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Phase classification: P=N/A --> P2
- Kymriah (tisagenlecleucel-T) / Novartis
Enrollment open: Study of Efficacy and Safety of CTL019 in Adult ALL Patients (clinicaltrials.gov) - Oct 15, 2014
P2, N=67, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Phase classification: P=N/A --> P2 Active, not recruiting --> Recruiting
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment change: Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Oct 10, 2014
P1/2, N=32, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Recruiting N=52 --> 32
- Trial primary completion date: Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome (clinicaltrials.gov) - Sep 30, 2014
P=N/A, N=30, Active, not recruiting, Sponsor: Rutgers, The State University of New Jersey
N=52 --> 32 Trial primary completion date: Dec 2013 --> May 2013
- Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment open: Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection (clinicaltrials.gov) - Sep 28, 2014
P1, N=72, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2013 --> May 2013 Not yet recruiting --> Recruiting
- OXS-1550 / GT Biopharma
Trial completion, Trial primary completion date: DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma (clinicaltrials.gov) - Sep 28, 2014
P1, N=30, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial primary completion date: Nov 2015 --> Sep 2014
- melphalan / Generic mfg.
Trial completion: Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases (clinicaltrials.gov) - Sep 22, 2014
P2, N=66, Completed, Sponsor: Comprehensive Cancer Center of Wake Forest University
Recruiting --> Completed | Trial primary completion date: Nov 2015 --> Sep 2014 Active, not recruiting --> Completed
- | Elitek (rasburicase) / Sanofi, Rituxan (rituximab) / Roche
Trial completion, Metastases: Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma (clinicaltrials.gov) - Sep 22, 2014
P2, N=97, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Cilcane (cilengitide) / Iceni Pharma
Trial completion, Metastases: EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer (clinicaltrials.gov) - Sep 17, 2014
P1, N=40, Completed, Sponsor: Indiana University School of Medicine
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion, Enrollment change, Trial primary completion date: Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma (clinicaltrials.gov) - Sep 16, 2014
P2, N=182, Completed, Sponsor: Northern Italy Leukemia Group
Active, not recruiting --> Completed Recruiting --> Completed | N=113 --> 182 | Trial primary completion date: Dec 2012 --> Jun 2014
- Rituxan (rituximab) / Roche
Trial primary completion date: Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma (clinicaltrials.gov) - Sep 11, 2014
P2, N=70, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Completed | N=113 --> 182 | Trial primary completion date: Dec 2012 --> Jun 2014 Trial primary completion date: Sep 2015 --> Sep 2016
- || denintuzumab mafodotin (SGN-CD19A) / Pfizer
Enrollment change, Trial primary completion date: A Safety Study of SGN-CD19A for B-Cell Lymphoma (clinicaltrials.gov) - Sep 8, 2014
P1, N=175, Recruiting, Sponsor: Seattle Genetics, Inc.
Trial primary completion date: Sep 2015 --> Sep 2016 N=120 --> 175 | Trial primary completion date: Dec 2015 --> May 2015
- | Trial completion: Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors (clinicaltrials.gov) - Sep 8, 2014
P1, N=0, Completed, Sponsor: Indiana University School of Medicine
N=120 --> 175 | Trial primary completion date: Dec 2015 --> May 2015 No longer recruiting --> Completed
- Elitek (rasburicase) / Sanofi
Trial primary completion date: Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies (clinicaltrials.gov) - Sep 4, 2014
P2, N=36, Recruiting, Sponsor: Roswell Park Cancer Institute
No longer recruiting --> Completed Trial primary completion date: Jul 2014 --> Jul 2015
- Zolinza (vorinostat) / Merck (MSD), Rituxan (rituximab) / Roche
Trial completion: Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma (clinicaltrials.gov) - Sep 4, 2014
P1/2, N=29, Completed, Sponsor: University of Washington
Trial primary completion date: Jul 2014 --> Jul 2015 Active, not recruiting --> Completed
- Imbruvica (ibrutinib) / AbbVie, J&J
Trial initiation date: Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection (clinicaltrials.gov) - Aug 27, 2014
P1, N=72, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Initiation date: May 2014 --> Aug 2014
- Zolinza (vorinostat) / Merck (MSD)
Trial completion, Combination therapy, Metastases: Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia (clinicaltrials.gov) - Aug 27, 2014
P1, N=80, Completed, Sponsor: National Cancer Institute (NCI)
Initiation date: May 2014 --> Aug 2014 Active, not recruiting --> Completed
- human allogeneic myeloid progenitor cells (CLT-008) / Cellerant Therap
Enrollment closed, Enrollment change, Trial primary completion date, Post-transplantation: Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy (clinicaltrials.gov) - Aug 22, 2014
P1, N=30, Active, not recruiting, Sponsor: Cellerant Therapeutics
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=40 --> 30 | Trial primary completion date: Dec 2013 --> Jun 2014
- ||| Elitek (rasburicase) / Sanofi, Rituxan (rituximab) / Roche
Metastases: Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma (clinicaltrials.gov) - Aug 22, 2014
P2, N=97, Active, not recruiting, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting | N=40 --> 30 | Trial primary completion date: Dec 2013 --> Jun 2014 Completed --> Active, not recruiting
- VS-4718 / Verastem
Trial initiation date, Trial primary completion date: Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Aug 19, 2014
P1, N=50, Not yet recruiting, Sponsor: Verastem, Inc.
Completed --> Active, not recruiting Initiation date: Nov 2014 --> Feb 2015 | Trial primary completion date: Jan 2016 --> Sep 2016
- Trial primary completion date, Post-transplantation: Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies (clinicaltrials.gov) - Aug 15, 2014
P2, N=42, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Initiation date: Nov 2014 --> Feb 2015 | Trial primary completion date: Jan 2016 --> Sep 2016 Trial primary completion date: Sep 2014 --> Jun 2014
- | VS-4718 / Verastem
New P1 trial: Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Aug 15, 2014
P1, N=50, Not yet recruiting, Sponsor: Verastem, Inc.
- Enrollment change: Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment (clinicaltrials.gov) - Aug 8, 2014
P1, N=0, Withdrawn, Sponsor: Children's Oncology Group
Trial primary completion date: Sep 2014 --> Jun 2014 N=36 --> 0
- Trial termination: Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL) (clinicaltrials.gov) - Aug 7, 2014
P3, N=52, Terminated, Sponsor: M.D. Anderson Cancer Center
N=36 --> 0 Completed --> Terminated; Terminated early due to futility.
- | Trial completion: American Ginseng in Treating Patients With Fatigue Caused by Cancer (clinicaltrials.gov) - Aug 6, 2014
P3, N=364, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Completed --> Terminated; Terminated early due to futility. Active, not recruiting --> Completed
- Bexxar (iodine I 131 tositumomab) / GSK
Trial completion: Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Aug 6, 2014
P1, N=38, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Bexxar (iodine I 131 tositumomab) / GSK
Trial completion, Enrollment change: Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Aug 6, 2014
P2, N=112, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=140 --> 112
- |||| peripheral blood stem cell transplantation / National Cancer Institute
Trial completion, Enrollment change, Trial initiation date: Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Hodgkin's or Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Aug 1, 2014
P2, N=69, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | N=140 --> 112 Active, not recruiting --> Completed | N=30 --> 69 | Initiation date: Jun 2002 --> Apr 1998
- || cyclophosphamide / Generic mfg.
Trial completion, Metastases: Combination Chemotherapy in Treating Children With Stage III or Stage IV Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 26, 2014
P3, N=20, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | N=30 --> 69 | Initiation date: Jun 2002 --> Apr 1998 Active, not recruiting --> Completed
- ||||||| Trial completion, Enrollment change: CCLG-NHL-9600: TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jul 24, 2014
P3, N=1148, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=900 --> 1148
- Intron A (interferon ?-2b) / Merck (MSD), Biogen, Roferon A (recombinant interferon alfa-2a) / Roche
Trial completion, Enrollment change: Interferon Alfa in Treating Children With HIV-Related Cancer (clinicaltrials.gov) - Jul 24, 2014
P2, N=8, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | N=900 --> 1148 Active, not recruiting --> Completed | N=30 --> 8
- Trial primary completion date, Metastases: Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants (clinicaltrials.gov) - Jul 23, 2014
P=N/A, N=48, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Active, not recruiting --> Completed | N=30 --> 8 Trial primary completion date: Oct 2009 --> Oct 2015
- || Enrollment closed: Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jul 15, 2014
P=N/A, N=100, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Oct 2009 --> Oct 2015 Recruiting --> Active, not recruiting
- Campath (alemtuzumab) / Sanofi
Enrollment change: Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer (clinicaltrials.gov) - Jun 27, 2014
P2, N=11, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Active, not recruiting N=100 --> 11
- Kymriah (tisagenlecleucel-T) / Novartis
Enrollment closed: Study of Efficacy and Safety of CTL019 in Adult ALL Patients (clinicaltrials.gov) - Jun 27, 2014
P2, N=67, Active, not recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
N=100 --> 11 Recruiting --> Active, not recruiting